Technicals for Sun Pharma Advanced Research Company Limited
The current reading of the STOCHASTIC is neutral for SPARC, with no...
More about Sun Pharma Advanced Research Company Limited
Fundamentals for Sun Pharma Advanced Research Company Limited
SPARC is projected to see revenue growth above last year's, which could...
Regulatory Filings for Sun Pharma Advanced Research Company Limited
The list of all important regulatory filings for Sun Pharma Advanced Research...
Elon Musk's Political Shift: Distancing from Current Administration
This article examines Elon Musk's recent comments distancing himself from the current...
The Future of American Innovation at Risk: A Look at Student Visa Policies
This article analyzes the potential economic implications of the U.S. decision to...
The Kaveri Engine: Navigating India's Aerospace Future
This article delves into the development saga of the Kaveri engine for...
Fundamentals for Sun Pharma Advanced Research Company Limited
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
Revenue projections:
SPARC is projected to see revenue growth above last year's, which could present an attractive opportunity for investors. If additional fundamental signals confirm this trend, it may indicate that the company is on a strong financial trajectory, making it a good time to invest.
Financial Ratios:
| currentRatio | 0.00000 |
|---|---|
| forwardPE | 0.00000 |
| debtToEquity | 0.00000 |
| earningsGrowth | 0.00000 |
| revenueGrowth | 0.07600 |
| grossMargins | 0.45713 |
| operatingMargins | -5.15292 |
| trailingEps | -11.97000 |
| forwardEps | 55.40000 |
Price projections:
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst technicals.
Lists of companies in NSE500 with the best and the worst technicals...
Companies with the best and the worst fundamentals.
Lists of companies in NSE500 with the best and the worst fundamentals...
Latest Regulatory Filings for NSE500
List of the latest important filings for NSE500....
Byju's: The Fall of a Giant in the EdTech Arena
The rise and fall of Byju's, the influential EdTech company, detailing its...
India Ascends: Surpassing Japan as the Fourth Largest Economy
This article discusses India's recent achievement of becoming the fourth-largest economy by...
Analyzing the Impact of Trump's 5% Remittance Tax on Indian Economy
This article analyzes the recently announced 5% remittance tax by the Trump...